[go: up one dir, main page]

WO2002070744A3 - Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds - Google Patents

Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds Download PDF

Info

Publication number
WO2002070744A3
WO2002070744A3 PCT/EP2002/002511 EP0202511W WO02070744A3 WO 2002070744 A3 WO2002070744 A3 WO 2002070744A3 EP 0202511 W EP0202511 W EP 0202511W WO 02070744 A3 WO02070744 A3 WO 02070744A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
screening compounds
regulatory genes
library assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/002511
Other languages
French (fr)
Other versions
WO2002070744A2 (en
Inventor
Es Helmuth Hendrikus Gerar Van
Godefridus Augustinus Michiels
Peter Herwig Maria Tomme
Reginald Christophe Xavie Brys
Rene Bernards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos Genomics NV
Original Assignee
Galapagos Genomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01870038A external-priority patent/EP1239038A1/en
Application filed by Galapagos Genomics NV filed Critical Galapagos Genomics NV
Priority to AU2002253104A priority Critical patent/AU2002253104A1/en
Publication of WO2002070744A2 publication Critical patent/WO2002070744A2/en
Anticipated expiration legal-status Critical
Publication of WO2002070744A3 publication Critical patent/WO2002070744A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the field of molecular genetics and medicine. In particular the present invention relates to the field of functional genonics. The present invention provides the methods and means for the identification of nucleic acid and the polypeptides encoded by these nucleic acids that have a function related to the E2F pathway, which were isolated in a high-throughput screening assay using the E2F transcription factor activity as a read-out. The identified compounds are suitable drug-targets to treat human diseases.
PCT/EP2002/002511 2001-03-07 2002-03-06 Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds Ceased WO2002070744A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002253104A AU2002253104A1 (en) 2001-03-07 2002-03-06 Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP01870038.5 2001-03-07
EP01870038A EP1239038A1 (en) 2001-03-07 2001-03-07 High-throughput identification of modulators of e2f activity
US28259001P 2001-04-09 2001-04-09
US60/282,590 2001-04-09
EP01870095.5 2001-05-02
EP01870095 2001-05-02
EP01870124 2001-06-08
EP01870124.3 2001-06-08

Publications (2)

Publication Number Publication Date
WO2002070744A2 WO2002070744A2 (en) 2002-09-12
WO2002070744A3 true WO2002070744A3 (en) 2003-10-09

Family

ID=27440168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002511 Ceased WO2002070744A2 (en) 2001-03-07 2002-03-06 Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds

Country Status (2)

Country Link
AU (1) AU2002253104A1 (en)
WO (1) WO2002070744A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014577A (en) 2004-06-14 2007-03-23 Galapagos Nv Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases.
EP2360474B1 (en) 2004-06-21 2013-07-24 Galapagos N.V. Methods and means for treatment of osteoarthritis
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
EP2162747B1 (en) 2007-06-20 2014-04-30 Galapagos N.V. Molecular targets and methods to identify compounds for treating bone and joint degenerative diseases

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033819A1 (en) * 1997-01-30 1998-08-06 New York University Cellular receptors for subgroup c adenoviruses and group b coxsackieviruses
WO1999050405A1 (en) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999054461A2 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of endometrium tumour tissue
WO1999055886A1 (en) * 1998-04-24 1999-11-04 Genova Pharmaceuticals Corporation Function-based gene discovery
WO1999060407A1 (en) * 1998-05-15 1999-11-25 Cancer Research Campaign Technogoly Limited Assays, methods and means for modulating e2f activity
WO1999064582A2 (en) * 1998-06-12 1999-12-16 Introgene B.V. High-throughput screening of gene function using libraries for functional genomics applications
US6048693A (en) * 1996-10-16 2000-04-11 Bittech, Inc. Phenotypic assays of cyclin/cyclin-dependent kinase function
WO2000056881A1 (en) * 1999-03-23 2000-09-28 Human Genome Sciences, Inc. 48 human secreted proteins
WO2001004296A1 (en) * 1999-07-12 2001-01-18 Mcgill University Rbp1 polypeptides and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048693A (en) * 1996-10-16 2000-04-11 Bittech, Inc. Phenotypic assays of cyclin/cyclin-dependent kinase function
WO1998033819A1 (en) * 1997-01-30 1998-08-06 New York University Cellular receptors for subgroup c adenoviruses and group b coxsackieviruses
WO1999050405A1 (en) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999054461A2 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of endometrium tumour tissue
WO1999055886A1 (en) * 1998-04-24 1999-11-04 Genova Pharmaceuticals Corporation Function-based gene discovery
WO1999060407A1 (en) * 1998-05-15 1999-11-25 Cancer Research Campaign Technogoly Limited Assays, methods and means for modulating e2f activity
WO1999064582A2 (en) * 1998-06-12 1999-12-16 Introgene B.V. High-throughput screening of gene function using libraries for functional genomics applications
WO2000056881A1 (en) * 1999-03-23 2000-09-28 Human Genome Sciences, Inc. 48 human secreted proteins
WO2001004296A1 (en) * 1999-07-12 2001-01-18 Mcgill University Rbp1 polypeptides and uses thereof

Also Published As

Publication number Publication date
WO2002070744A2 (en) 2002-09-12
AU2002253104A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO2005042716A3 (en) Nucleic acid binding oligonucleotides
WO2005005604A3 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO1999053040A3 (en) Human nucleic acid sequences from ovarian tumour tissue
WO2005030121A3 (en) Compounds, compositions and methods
WO2001004314A3 (en) Nucleic acid molecules and proteins associated with sterol synthesis and metabolism
WO2004047863A3 (en) Genetic products differentially expressed in tumors and the use thereof
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2004013312A3 (en) Tocopherol biosynthesis related genes and uses thereof
WO2003016482A3 (en) Methyltransferase genes and uses thereof
WO1999066028A3 (en) Genes for the biosynthesis of epothilones
WO2004063213A3 (en) Peptides which target tumor and endothelial cells, compositions and uses thereof
WO2002048329A3 (en) Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2003076631A3 (en) Genetic products differentially expressed in tumors and use thereof
WO2005026205A3 (en) Genetic products which are differentially expressed in tumours and use thereof
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
WO2002070744A3 (en) Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds
WO2005079367A3 (en) Schizochytrium fatty acid synthase (fas) and products and methods related thereto
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO2005067648A3 (en) Multiplex spatial profiling of gene expression
WO2004009822A3 (en) Use of specific myb genes for the production of transgenic plants tolerant to biotic and abiotic stresses
WO2001064876A3 (en) Human schizophrenia gene
WO2000008134A3 (en) HUMAN HtrA SERINE PROTEASE
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
WO2004056965A3 (en) Nucleic acids encoding antifungal drug targets and methods of use
WO2003033692A3 (en) Use of the adenoviral e2 late promoter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP